On Thursday, we brought you a sweeping piece that touched on a multitude of topics that are near and dear to us including, but not limited to: the extent to which modern market structure poses a bigger risk than most people are willing to admit; and the mechanisms and dynamics that transformed “BTFD” from a derisive meme…
The University of Michigan Preliminary Consumer Sentiment for May came in at 98.8, unchanged from the April Final reading. Investing.com had forecast 98.5. Surveys of Consumers chief economist, Richard Curtin, makes the following comments: Consumer sentiment remained unchanged in early May from the April survey. The Expectations Index gained 1.1 points and the Current Conditions Index fell…
Risk lovers seeking healthy returns over a fairly long investment horizon may opt for technology mutual funds. It is believed that the technology sector is poised for a brighter earnings performance than the other sectors due to greater demand for technology and innovation. Improving industry fundamentals and emerging technologies such as wearables, VR headsets, drones,…
“Strategy without tactics is the slowest route to victory. Tactics without strategy is the noise before defeat.” – Sun Tzu: The Art Of War The biggest mistake investors make over the long-term is investing without a strategy. The point that Sun Tzu was making, as it relates to investing, is that having a strategy, such as buying…
This week, one of the best performers was crude oil. The price of Brent and WTI surged by 4.8% and 3.6% respectively. They are now trading at the highest level since 2014. The gain came as Donald Trump moved to fulfill his campaign promise of getting out of the Joint Comprehensive Plan of Action (JCPOA)…
Recap from April’s Picks Our Most Attractive Stocks (-0.4%) underperformed the S&P 500 (+0.4%) last month. Most Attractive Large Cap stock USANA Health Sciences (USNA) gained 15%. Most Attractive Small Cap stock Heidrick & Struggles International (HSII) was up 21%. Overall, 16 out of the 40 Most Attractive stocks outperformed the S&P 500 in April….
DOW, S&P BREAKOUTS AS USD-WEAKNESS SHOWS UP It’s been a fairly climactic week across global markets, and for US equity traders the release of that building tension has worked out in a positive way. While the S&P 500 and the Dow had spent much of the prior three months coiling-up into congestion patterns, giving the appearance of…
Exelixis (EXEL – Free Report) is a $6 billion biotechnology company focused on cancer R&D and the producer of cabozantinib (sold under the brand names Cabometyx and Cometriq), a treatment approved by the FDA for several indications: medullary thyroid cancer, a second line treatment for renal cell carcinoma (RCC), and clinical activity in several other types of metastatic…
Exelixis (EXEL – Free Report) is a $6 billion biotechnology company focused on cancer R&D and the producer of cabozantinib (sold under the brand names Cabometyx and Cometriq), a treatment approved by the FDA for several indications: medullary thyroid cancer, a second line treatment for renal cell carcinoma (RCC), and clinical activity in several other types of metastatic…
JPMorgan analyst Philip Cusick upgraded Verizon Communications to Overweight from Neutral with an unchanged price target of $58. The shares closed yesterday up 81c to $47.20. After meeting with CEO Lowell McAdam, Cusick says he has a better understanding that Verizon’s “organic approach to wireless has the company on an increasingly stable footing.” Further,…
